ReviewClinical microbiology reviews2001
Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review.
Review in Clinical microbiology reviews, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 223 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
223 citing papers in PubMed, 3 syntheses or guidelines pooled it, 590 citations in OpenAlex.
- Periodontal status and chronic obstructive pulmonary disease (COPD) exacerbations: a systematic review.BMC oral health · 2021Pooled it
- Clinical Features and Laboratory Examination to Identify Severe Patients with COVID-19: A Systematic Review and Meta-Analysis.BioMed research international · 2021Pooled it
- Bacterial infections in acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis.Infection · 2020Pooled it
- Chlorhexidine oral rinses for symptomatic COPD: a randomised, blind, placebo-controlled preliminary study.BMJ open · 2021Trial
- Neutrophil elastase as a biomarker for bacterial infection in COPD.Respiratory research · 2019Trial
- Point-of-care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD.International journal of chronic obstructive pulmonary disease · 2016Trial
- Prognostic impact of lung diffusion capacity in patients with early-stage lung cancer achieving 5-year postoperative recurrence-free survival: propensity score matching analysis.General thoracic and cardiovascular surgery · 2026Article
- Single-bacterial cell insights into mechanisms of ceftriaxone resistance in Neisseria subflava.Nature communications · 2026Article
- Circulating cytokines mediate the risk of COPD: A mediation analysis based on 473 gut microbiota and 91 circulating cytokines.Medicine · 2026Article
- Prediction Score ofInternational journal of chronic obstructive pulmonary disease · 2026Article
- Molecular insights into lower respiratory tract microbiota reveal disease-specific biomarkers and shared microbial networks in asthma and COPD.Frontiers in cellular and infection microbiology · 2026Article
- Mangiferin Against Respiratory Diseases: Pharmacological Targets and Prospects.Pharmacology research & perspectives · 2025Review
- A Lymphocyte Subset-Based Prediction Model for Refractory Community-Acquired Pneumonia in Immunocompetent Patients.Diagnostics (Basel, Switzerland) · 2025Article
- Analyzing Clinical Parameters and Bacterial Profiles to Uncover the COPD Exacerbations: A Focus on Intensive Care Unit Challenges.Medicina (Kaunas, Lithuania) · 2025Article
- Clinical Significance of Various Pathogens Identified in Patients Experiencing Acute Exacerbations of COPD: A Multi-center Study in South Korea.Tuberculosis and respiratory diseases · 2025Article
- Exploiting haem-iron dependence of nontypeableFrontiers in cellular and infection microbiology · 2025Review
- Antimicrobial effect of benzbromarone combined with colistin against multidrug-resistant bacteria.Frontiers in medicine · 2025Article
- Respiratory Pathogens at Exacerbation in Chronic Bronchitis With Airway Bacterial Colonisation: A Cohort Study.The clinical respiratory journal · 2024Article
- Microcin C7 as a Potential Antibacterial-Immunomodulatory Agent in the Postantibiotic Era: Overview of Its Bioactivity Aspects and Applications.International journal of molecular sciences · 2024Review
- National trend in the prevalence and mortality of COPD in South Korea from 2008 to 2017.BMJ open respiratory research · 2024Article
163 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States. The precise role of bacterial infection in the course and pathogenesis of COPD has been a source of controversy for decades. Chronic bacterial colonization of the lower airways contributes to airway inflammation; more research is needed to test the hypothesis that this bacterial colonization accelerates the progressive decline in lung function seen in COPD (the vicious circle hypothesis). The course of COPD is characterized by intermittent exacerbations of the disease. Studies of samples obtained by bronchoscopy with the protected specimen brush, analysis of the human immune response with appropriate immunoassays, and antibiotic trials reveal that approximately half of exacerbations are caused by bacteria. Nontypeable Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae are the most common causes of exacerbations, while Chlamydia pneumoniae causes a small proportion. The role of Haemophilus parainfluenzae and gram-negative bacilli remains to be established. Recent progress in studies of the molecular mechanisms of pathogenesis of infection in the human respiratory tract and in vaccine development guided by such studies promises to lead to novel ways to treat and prevent bacterial infections in COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.